List view / Grid view

Articles

Screening In-Depth Focus 2016

11 December 2016 | By , , ,

In this Screening In-Depth Focus, scientists from the Assay Development and Screening Platform of Helmholtz Zentrum München provide an overview of different high-throughput screening (HTS)-applicable assay types that can be applied to drug discovery campaigns. Plus an interview with Lee Babiss, CEO of drug discovery firm X-Rx, on the benefits…

Next-Generation Sequencing In-Depth Focus 2016

11 December 2016 | By ,

NGS technologies have been employed in a wide range of areas in drug discovery, including drug target identification, biomarker discovery and biopharmaceutics development. Pushpanathan Muthuirulan of the National Institutes of Health gives us an overview of this in his article in our NGS In-Depth Focus. Meanwhile, the possibilities that RNA-Seq…

Drug Target Review – Issue #4 2016

11 December 2016 | By Drug Target Review

Included in this issue: Profiling proteins produced by cells to provide information about cell signalling pathways; HTS assays for the identification of small-molecule inhibitors of deubiquitinating enzymes; Preventing the spread of infectious diseases in transport hubs...

Valid biomarker signatures from liquid biopsies – how to standardise NGS

6 December 2016 | By , ,

The advent of next-generation sequencing (NGS) techniques has revolutionised transcriptomics research and opened numerous avenues for scientific and clinical applications. While reverse transcriptase quantitative real-time polymerase chain reaction (RT-qPCR) is still considered the gold standard of gene expression analysis, its high throughput, single-nucleotide resolution and ever-plummeting costs have made NGS…

How artificial intelligence is the future of pharma

5 December 2016 | By Professor Jackie Hunter, BenevolentBio

Artificial Intelligence and machine learning present the industry with a real opportunity to do R&D differently, writes BenevolentBio's Jackie Hunter...

HTS assays for the identification of small-molecule inhibitors of deubiquitinating enzymes

4 December 2016 | By , ,

The covalent modification of proteins by the attachment of ubiquitin (ubiquitination) is best known for its function to label proteins for proteasomal degradation. However, ubiquitination also plays non-proteasomal roles during signal transduction, DNA repair and protein sorting...

D is for Diabetes

17 November 2016 | By Niamh Louise Marriott, Digital Content Producer

D is for Diabetes - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research into Diabetes...

C is for CRISPR

16 November 2016 | By Niamh Louise Marriott, Digital Content Producer

C is for CRISPR - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research of CRISPR technology

B is for Biomarkers

15 November 2016 | By Niamh Louise Marriott, Digital Content Producer

B is for Biomarkers - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the subject of biomarkers.